Smartleaf Asset Management’s Blueprint Medicines BPMC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
Sell
-94
Closed -$12K 3009
2025
Q2
$12K Sell
94
-55
-37% -$5.71K ﹤0.01% 1760
2025
Q1
$13.2K Sell
149
-46
-24% -$4.49K ﹤0.01% 1812
2024
Q4
$16.9K Buy
195
+25
+15% +$2.29K ﹤0.01% 1740
2024
Q3
$15.7K Buy
170
+61
+56% +$6.06K ﹤0.01% 1490
2024
Q2
$11.8K Buy
+109
New +$10.9K ﹤0.01% 1326

Other funds holding BPMC

Smartleaf Asset Management's BPMC Position: Q3 2025 in Review

Smartleaf Asset Management sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 94 shares — an estimated $12K sold.

Smartleaf Asset Management first reported a position in BPMC in Q2 2024 and held it in 5 quarters. The position peaked at $16.9K in Q4 2024. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

  • Smartleaf Asset Management reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
  • Smartleaf Asset Management sold 94 Blueprint Medicines shares in Q3 2025, an estimated $12K.
  • Smartleaf Asset Management first reported a position in Blueprint Medicines in Q2 2024 and held it in 5 quarters.
  • Smartleaf Asset Management's Blueprint Medicines position peaked at $16.9K in Q4 2024.
  • 5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on Smartleaf Asset Management's 13F filing for Q3 2025, filed 5 Nov 2025.